BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2475955)

  • 1. [The diagnostic and prognostic value of tumor markers in nonseminomatous stage-III to -IV testicular tumors].
    Sakalo VS; Klimenko IA; Iaremko VN; Zaparin VK
    Urol Nefrol (Mosk); 1989; (3):42-6. PubMed ID: 2475955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified neck dissection for metastatic nonseminomatous testicular carcinoma.
    Weisberger EC; McBride LC
    Laryngoscope; 1999 Aug; 109(8):1241-4. PubMed ID: 10443827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors in metastatic nonseminomatous germ cell tumours.
    Hanson PR; Belitsky P; Millard OH; Lannon SG
    Can J Surg; 1993 Dec; 36(6):537-40. PubMed ID: 7504978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor markers in patients with non-seminomatous germ cell tumors of the testis.
    Willemse PH; Sleijfer DT; Schraffordt Koops H; De Bruijn HW; Oosterhuis JW; Brouwers TM; Ockhuizen T; Marrink J
    Oncodev Biol Med; 1981; 2(1-2):117-28. PubMed ID: 6170952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers.
    Habuchi T; Kamoto T; Hara I; Kawai K; Nakao M; Nonomura N; Kobayashi T; Ogawa O; Kamidono S; Akaza H; Okuyama A; Kato T; Miki T
    Cancer; 2003 Oct; 98(8):1635-42. PubMed ID: 14534879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors.
    Beck SD; Foster RS; Bihrle R; Donohue JP
    Urology; 2007 Mar; 69(3):557-9. PubMed ID: 17382165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Metastasis and markers].
    Trinchieri A; Rovera F; Longo G; Del Nero A; Zanetti G; Austoni E
    Arch Ital Urol Nefrol Androl; 1992 Mar; 64(1):27-30. PubMed ID: 1373913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of tumor marker determinations in testicular cancer patients.
    Kühböck J; Aiginger P; Kuzmits R; Spona J
    Cancer Detect Prev; 1987; 10(5-6):389-92. PubMed ID: 2436782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor markers in testicular germ cell tumors related to the stage of the disease at the time of diagnosis.
    Jacobsen GK
    Oncodev Biol Med; 1983; 4(6):C39-44. PubMed ID: 6196749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors?
    Gerl A; Lamerz R; Clemm C; Mann K; Hartenstein R; Wilmanns W
    Clin Cancer Res; 1996 Sep; 2(9):1565-70. PubMed ID: 9816334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-fetoprotein, and human chorionic gonadotrophin indicates a favorable prognostic subgroup within the embryonal carcinoma germ cell tumor.
    Mazumdar M; Bacik J; Tickoo SK; Dobrzynski D; Donadio A; Bajorin D; Motzer R; Reuter V; Bosl GJ
    J Clin Oncol; 2003 Jul; 21(14):2679-88. PubMed ID: 12860944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors in nonseminomatous testicular cancer.
    Javadpour N
    Prog Clin Biol Res; 1985; 203():271-86. PubMed ID: 2421330
    [No Abstract]   [Full Text] [Related]  

  • 13. The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers.
    Saxman SB; Nichols CR; Foster RS; Messemer JE; Donohue JP; Einhorn LH
    J Urol; 1996 Feb; 155(2):587-9. PubMed ID: 8558665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Usefulness of tumor markers in the treatment of germ cell tumors].
    Germá Lluch JR; García del Muro X; Galán MC
    Arch Esp Urol; 2000; 53(6):460-8. PubMed ID: 11002513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The case for observation of patients with clinical stage I nonseminomatous germ cell testicular tumors.
    Swanson DA
    Semin Urol; 1993 May; 11(2):92-8. PubMed ID: 7689741
    [No Abstract]   [Full Text] [Related]  

  • 16. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors.
    Fizazi K; Culine S; Kramar A; Amato RJ; Bouzy J; Chen I; Droz JP; Logothetis CJ
    J Clin Oncol; 2004 Oct; 22(19):3868-76. PubMed ID: 15302906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonseminomatous germ cell testicular tumors clinical stage I: differentiated therapeutic approach in comparison with therapeutic approach using surveillance strategy only.
    Ondrus D; Ondrusova M; Hornak M; Matoska J
    Neoplasma; 2007; 54(5):437-42. PubMed ID: 17688374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lactate dehydrogenase and its isoenzymes in testicular germ cell tumors: an overview.
    von Eyben FE
    Oncodev Biol Med; 1983; 4(6):395-414. PubMed ID: 6196755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor markers in testis cancer.
    Klein EA
    Urol Clin North Am; 1993 Feb; 20(1):67-73. PubMed ID: 7679533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
    Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
    Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.